Optimizing the therapeutic approach of transurethral alprostadil

BJU International

Volumn 86, Issue 1, 2000, Pages 68-74

  Ekman, P ^a,e   Sjogren L ^d   Englund, G ^c   Persson, B E ^b  

^a Department of Molecular Medicine and Surgery   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^c ROYAL INSTITUTE OF TECHNOLOGY   (Sweden)

^d Clinical Research   (Sweden)

^e KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Alprostadil; Dose; Erectile dysfunction; Erection Assessment Scale (EAS); International Index of Erectile Function (IIEF); MUSE( )

Indexed keywords

PROSTAGLANDIN E1;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; ERECTILE DYSFUNCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PAIN; PENIS; PRIORITY JOURNAL; SEXUAL INTERCOURSE;

ADULT; AGED; ALPROSTADIL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION ROUTES; HUMANS; IMPOTENCE; MALE; MIDDLE AGED; TREATMENT OUTCOME; URETHRA; VASODILATOR AGENTS;

EID: 0033946733     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410X.2000.00723.x     Document Type: Article

References (15)

1. 1 Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994; 151: 54-61
2. 2 Virag R. Intracavernous injection of papaverine for erectile failure. Lancet 1982; 2: 938
3. 3 Brindley GS. Cavernosal alpha-blockage: a new technique for investigating and treating erectile impotence. Br J Psychiatry 1983; 143: 332-7
4. 4 Hedlund H, Andersson KE. Contraction and relaxation induced by some prostanoids in isolated human penile erectile tissue and cavernous artery. J Urol 1985; 134: 1245-50
5. 5 Ishii N, Watanabe H, Irisawa C et al. Intracavernous injection of prostaglandin E1 for the treatment of erectile impotence. J Urol 1989; 141: 323-5
6. 6 Irwin K. High attrition rate with intracavernous injection of prostaglandin E1 for impotency. Urology 1994; 43: 84-7
7. 7 Costabile RA, Spevak M, Fishman IJ et al. Efficacy and safety of transurethral alprostadil in patients with erectile dysfunction following radical prostatectomy. J Urol 1998; 160: 1325-8
8. 8 Fulgham PF, Cochran JS, Denman JL et al. Disappointing initial results with transurethral alprostadil for erectile dysfunction in a urology practice setting. J Urol 1998; 160: 2041-6
9. 9 Hellstrom WJ, Bennett AH, Gesundheit N et al. A double blind, placebo-controlled evaluation of the erectile response to transurethral alprostadil. Urology 1996; 48: 851-6
10. 10 Padma-Nathan H, Hellstrom WJ, Kaiser FE et al. Treatment of men with erectile dysfunction with transurethral alprostadil. N Engl J Med 1997; 336: 1-7
11. 11 Williams G, Abbou CC, Amar ET et al. Efficacy and safety of transurethral alprostadil therapy in men with erectile dysfunction. Br J Urol 1998; 81: 889-94
12. 12 Waldhauser M, Schramek P. Efficiency and side effects of prostaglandin E1 in the treatment of erectile dysfunction. J Urol 1988; 140: 525-7
13. 13 Rosen RC, Riley A, Wagner G, Ostreloh IH, Kirkpatrick J, Mishra A. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 1997; 49: 822-30
14. 14 Peterson CA, Bennett AH, Hellstrom WJ et al. Erectile response to transurethral alprostadil, prazosin and alprostadil-prazosin combinations. J Urol 1998; 159: 1523-7
15. 15 Rosen RC, Johnson RW. Constructing and evaluating the 'Sexual Health Inventory for Men; IIEF-5' as a diagnostic tool for erectile dysfunction (ED). Int J Impotence Res 1998; 10: 35